rabeprazole has been researched along with Pyrosis in 39 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This systematic review and network meta-analysis aimed to assess the relative efficacy of vonoprazan and proton pump inhibitors (PPIs) on early heartburn symptom resolution in patients with erosive esophagitis." | 9.22 | Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis. ( Deguchi, H; Fernandez, J; Fujimori, I; Igarashi, A; Nakano, H; Oshima, T, 2022) |
| "Patients with LA grade C or D oesophagitis were randomised to rabeprazole-ER 50 mg or esomeprazole 40 mg once daily in two identical 8-week double-blind trials (N = 2130)." | 9.15 | Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies. ( Chou, C; Goldstein, MJ; Ibegbu, I; Johnson, DA; Katz, PO; Laine, L; Lu, Y; Rossiter, G, 2011) |
| "The primary efficacy end point, mean percentage of heartburn-free days, was significantly greater with rabeprazole vs." | 9.14 | Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study. ( Delemos, B; Fass, R; Kao, R; Lu, Y; Nazareno, L; Xiang, J, 2010) |
| "Rabeprazole 20 mg was non-inferior to esomeprazole 40 mg for complete resolution of regurgitation and satisfactory resolution of heartburn and regurgitation." | 9.14 | Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. ( Eggleston, A; Holtmann, G; Katelaris, PH; Nandurkar, S; Thorpe, P, 2009) |
| "In GERD patients with nocturnal heartburn, rabeprazole 20 mg was significantly more effective than pantoprazole 40 mg in percentage time with intragastric pH >4 during the nighttime, daytime, and 24-h periods." | 9.14 | Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. ( Delemos, B; Ieni, J; Lococo, J; Miner, P; Xiang, J, 2010) |
| "In GERD patients with nocturnal heartburn, a single oral dose of rabeprazole 20 mg increased intragastric pH more than pantoprazole 40 mg did throughout the 24 h after dosing." | 9.12 | Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. ( Baisley, K; Boyce, M; Delemos, B; Lee, D; Lomax, K; Morocutti, A; Warrington, S, 2007) |
| "This randomized, open-label study enrolled 331 GERD (heartburn-predominant) patients with a pre-existing proton pump inhibitor history of one month or longer, to an acute four-week trial with 20 mg rabeprazole daily for heartburn management." | 9.12 | Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. ( Camacho, F; Dinniwell, J; Horbay, GL; Husein-Bhabha, FA; Morgan, DG; O'Mahony, MF; O'Mahony, WF; Roy, J, 2007) |
| " The numbers of patients with relief from heartburn on day 4 were similar in the two groups (84% for rabeprazole; 95% confidence interval, 76-90%; 83% for omeprazole; 95% confidence interval, 75-89%)." | 9.10 | A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. ( Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M, 2002) |
| "Rabeprazole was superior to ranitidine in esophageal healing and symptom relief in patients with erosive gastroesophageal reflux disease, and was equally well tolerated." | 9.09 | Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. ( Farley, A; Humphries, TJ; Wruble, LD, 2000) |
| " These data suggest that administration of a PPI before the evening meal maximizes acid control and would be the preferred dosing schedule in GERD patients, particularly those with nocturnal symptoms." | 6.71 | Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. ( McCallum, RW; Olyaee, M; Pehlivanov, ND; Sarosiek, I, 2003) |
| "Rabeprazole 10 mg/day was administered for 4 weeks to 180 patients who kept symptom diaries." | 5.34 | Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. ( Chiba, T; Fujiwara, Y; Furuta, T; Habu, Y; Hongo, M; Ito, M; Kinoshita, Y; Koike, T; Miwa, H; Nagahara, A; Sasaki, M; Wada, T, 2007) |
| "This systematic review and network meta-analysis aimed to assess the relative efficacy of vonoprazan and proton pump inhibitors (PPIs) on early heartburn symptom resolution in patients with erosive esophagitis." | 5.22 | Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis. ( Deguchi, H; Fernandez, J; Fujimori, I; Igarashi, A; Nakano, H; Oshima, T, 2022) |
| "Complete heartburn relief rates were 21% in placebo, 34% in rabeprazole 5 mg and 44% in rabeprazole 10 mg (5 mg vs." | 5.15 | Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. ( Ashida, K; Hongo, M; Kinoshita, Y, 2011) |
| "Patients with LA grade C or D oesophagitis were randomised to rabeprazole-ER 50 mg or esomeprazole 40 mg once daily in two identical 8-week double-blind trials (N = 2130)." | 5.15 | Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies. ( Chou, C; Goldstein, MJ; Ibegbu, I; Johnson, DA; Katz, PO; Laine, L; Lu, Y; Rossiter, G, 2011) |
| "Administration of 5 mg and 10 mg rabeprazole sufficiently inhibited pathological gastroesophageal acid reflux and relieved heartburn episodes in NERD patients who did not respond to an antacid." | 5.15 | Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study. ( Ashida, K; Hongo, M; Kinoshita, Y, 2011) |
| "Patients with symptomatic gastroesophageal reflux disease (GERD) (NERD and RE) were treated with rabeprazole (RPZ) 10 mg once daily for 4 weeks." | 5.15 | Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research G ( Chiba, T; Fujiwara, Y; Furuta, T; Hongo, M; Ishihara, S; Kinoshita, Y; Koike, T; Kusano, M; Shimatani, T; Sugimoto, M, 2011) |
| "The primary efficacy end point, mean percentage of heartburn-free days, was significantly greater with rabeprazole vs." | 5.14 | Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study. ( Delemos, B; Fass, R; Kao, R; Lu, Y; Nazareno, L; Xiang, J, 2010) |
| "In GERD patients with nocturnal heartburn, rabeprazole 20 mg was significantly more effective than pantoprazole 40 mg in percentage time with intragastric pH >4 during the nighttime, daytime, and 24-h periods." | 5.14 | Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. ( Delemos, B; Ieni, J; Lococo, J; Miner, P; Xiang, J, 2010) |
| "In patients with endoscopy-confirmed erosive esophagitis treated with once-daily rabeprazole 20 mg, prompt and continuing improvements were seen in daytime and nighttime heartburn, belching, regurgitation, and dysphagia." | 5.14 | Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results. ( Cutler, A; Delemos, B; Murthy, A; Robinson, M, 2010) |
| "Rabeprazole 20 mg was non-inferior to esomeprazole 40 mg for complete resolution of regurgitation and satisfactory resolution of heartburn and regurgitation." | 5.14 | Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. ( Eggleston, A; Holtmann, G; Katelaris, PH; Nandurkar, S; Thorpe, P, 2009) |
| "In GERD patients with nocturnal heartburn, a single oral dose of rabeprazole 20 mg increased intragastric pH more than pantoprazole 40 mg did throughout the 24 h after dosing." | 5.12 | Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. ( Baisley, K; Boyce, M; Delemos, B; Lee, D; Lomax, K; Morocutti, A; Warrington, S, 2007) |
| "This randomized, open-label study enrolled 331 GERD (heartburn-predominant) patients with a pre-existing proton pump inhibitor history of one month or longer, to an acute four-week trial with 20 mg rabeprazole daily for heartburn management." | 5.12 | Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. ( Camacho, F; Dinniwell, J; Horbay, GL; Husein-Bhabha, FA; Morgan, DG; O'Mahony, MF; O'Mahony, WF; Roy, J, 2007) |
| "Oesophageal pH and heartburn severity were determined in 27 GERD subjects at baseline and on days 1, 2 and 8 of treatment with 20 mg omeprazole or 20 mg rabeprazole in a randomized, two-way crossover fashion." | 5.10 | Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor. ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| "The mean heartburn score in patients administered rabeprazole decreased more rapidly than those given the other PPI." | 5.10 | Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. ( Adachi, K; Fujishiro, H; Hamamoto, N; Hashimoto, T; Hattori, S; Hirakawa, K; Kaji, T; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miyake, T; Niigaki, M; Ono, M; Shizuku, T; Suetsugu, H; Taniura, H; Yagi, J; Yamamoto, S, 2003) |
| "On day 1, rabeprazole significantly decreased daytime and night-time heartburn severity, regurgitation and belching." | 5.10 | Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. ( Fitzgerald, S; Hegedus, R; Jokubaitis, L; Murthy, A; Robinson, M, 2002) |
| " The numbers of patients with relief from heartburn on day 4 were similar in the two groups (84% for rabeprazole; 95% confidence interval, 76-90%; 83% for omeprazole; 95% confidence interval, 75-89%)." | 5.10 | A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. ( Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M, 2002) |
| "Rabeprazole was superior to ranitidine in esophageal healing and symptom relief in patients with erosive gastroesophageal reflux disease, and was equally well tolerated." | 5.09 | Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. ( Farley, A; Humphries, TJ; Wruble, LD, 2000) |
| "The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief." | 4.95 | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. ( Li, MJ; Li, Q; Liu, LQ; Sun, M, 2017) |
| "The extraesophageal manifestations of gastroesophageal reflux disease (GERD) are more difficult to manage than the typical symptoms." | 2.94 | Efficacy of a high-dose proton pump inhibitor in patients with gastroesophageal reflux disease: a single center, randomized, open-label trial. ( Cho, JH; Kim, N; Lee, DH; Park, YS; Shin, CM; Yoon, H, 2020) |
| "Rabeprazole has a comparable efficacy compared to ranitidine when given on-demand for the treatment of NERD." | 2.77 | A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease. ( Aswad, R; El-Samad, S; Haddad, R; Hashash, JG; Jamali, FR; Kobeissy, AA; Ladki, R; Skoury, AM; Soweid, AM, 2012) |
| " Fifteen healthy Japanese volunteers are dosed for 7 days in a 5-way randomly crossover trial: placebo, aspirin 100 mg, rabeprazole 10 mg, and aspirin 100 mg plus rabeprazole 10 mg either once daily or 4 times per day." | 2.75 | Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. ( Furuta, T; Hishida, A; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Sugimura, H; Tanaka, T; Yamade, M, 2010) |
| " These data suggest that administration of a PPI before the evening meal maximizes acid control and would be the preferred dosing schedule in GERD patients, particularly those with nocturnal symptoms." | 2.71 | Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. ( McCallum, RW; Olyaee, M; Pehlivanov, ND; Sarosiek, I, 2003) |
| "Heartburn was a poor predictor of whether patients with chest pain were GORD-positive or GORD-negative by objective testing." | 2.47 | Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. ( Howden, CW; Hughes, N; Kahrilas, PJ, 2011) |
| "Whether these patients are part of the GERD spectrum or have another diagnosis is not clear." | 2.43 | Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. ( DeVault, KR, 2006) |
| "Symptom eradication in patients with Barrett's esophagus (BE) does not guarantee control of acid or duodenogastroesophageal reflux (DGER)." | 1.42 | Control of acid and duodenogastroesophageal reflux (DGER) in patients with Barrett's esophagus. ( Bhat, YM; Falk, GW; Maqbool, S; Richter, JE; Vaezi, MF; Yachimski, P, 2015) |
| "To clarify the pathogenesis of gastroesophageal reflux disease symptoms in non-erosive reflux disease (NERD) patients." | 1.42 | Characteristics of symptomatic reflux episodes in Japanese proton pump inhibitor-refractory non-erosive reflux disease patients. ( Ara, N; Asano, N; Hatta, W; Iijima, K; Kikuchi, H; Koike, T; Nakagawa, K; Saito, M; Shimosegawa, T; Uno, K, 2015) |
| "Japanese GERD patients are often obese, as reported previously, but some GERD patients are underweight." | 1.38 | Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors. ( Hongo, M; Kusano, M; Miwa, H, 2012) |
| "Of 132 GERD patients enrolled, 101 completed the study." | 1.35 | The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. ( Adlis, SA; Chey, WD; Nojkov, B; Rai, J; Rubenstein, JH; Saad, R; Shaw, MJ; Weinman, B, 2008) |
| "Rabeprazole 10 mg/day was administered for 4 weeks to 180 patients who kept symptom diaries." | 1.34 | Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. ( Chiba, T; Fujiwara, Y; Furuta, T; Habu, Y; Hongo, M; Ito, M; Kinoshita, Y; Koike, T; Miwa, H; Nagahara, A; Sasaki, M; Wada, T, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (48.72) | 29.6817 |
| 2010's | 17 (43.59) | 24.3611 |
| 2020's | 3 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Oshima, T | 1 |
| Igarashi, A | 1 |
| Nakano, H | 1 |
| Deguchi, H | 1 |
| Fujimori, I | 1 |
| Fernandez, J | 1 |
| Barberio, B | 1 |
| Visaggi, P | 1 |
| Savarino, E | 2 |
| de Bortoli, N | 1 |
| Black, CJ | 1 |
| Ford, AC | 1 |
| Cho, JH | 1 |
| Shin, CM | 1 |
| Yoon, H | 1 |
| Park, YS | 1 |
| Kim, N | 1 |
| Lee, DH | 1 |
| Li, MJ | 1 |
| Li, Q | 1 |
| Sun, M | 1 |
| Liu, LQ | 1 |
| Yachimski, P | 1 |
| Maqbool, S | 1 |
| Bhat, YM | 1 |
| Richter, JE | 1 |
| Falk, GW | 1 |
| Vaezi, MF | 1 |
| Nakagawa, K | 1 |
| Koike, T | 3 |
| Iijima, K | 1 |
| Saito, M | 1 |
| Kikuchi, H | 1 |
| Hatta, W | 1 |
| Ara, N | 1 |
| Uno, K | 1 |
| Asano, N | 1 |
| Shimosegawa, T | 1 |
| Eggleston, A | 1 |
| Katelaris, PH | 1 |
| Nandurkar, S | 1 |
| Thorpe, P | 1 |
| Holtmann, G | 2 |
| Cutler, A | 1 |
| Robinson, M | 3 |
| Murthy, A | 2 |
| Delemos, B | 4 |
| Sugimoto, M | 3 |
| Nishino, M | 2 |
| Kodaira, C | 1 |
| Yamade, M | 1 |
| Ikuma, M | 1 |
| Tanaka, T | 1 |
| Sugimura, H | 1 |
| Hishida, A | 1 |
| Furuta, T | 3 |
| Miner, P | 1 |
| Xiang, J | 2 |
| Lococo, J | 1 |
| Ieni, J | 1 |
| Fass, R | 1 |
| Nazareno, L | 1 |
| Kao, R | 1 |
| Lu, Y | 2 |
| Iwakiri, K | 1 |
| Sano, H | 1 |
| Tanaka, Y | 1 |
| Kawami, N | 1 |
| Umezawa, M | 1 |
| Futagami, S | 1 |
| Hoshihara, Y | 1 |
| Nomura, T | 1 |
| Miyashita, M | 1 |
| Sakamoto, C | 1 |
| Kinoshita, Y | 6 |
| Ashida, K | 2 |
| Hongo, M | 6 |
| Laine, L | 1 |
| Katz, PO | 1 |
| Johnson, DA | 1 |
| Ibegbu, I | 1 |
| Goldstein, MJ | 1 |
| Chou, C | 1 |
| Rossiter, G | 1 |
| Kahrilas, PJ | 1 |
| Hughes, N | 1 |
| Howden, CW | 1 |
| Wang, AJ | 1 |
| Liang, MJ | 1 |
| Jiang, AY | 1 |
| Lin, JK | 1 |
| Xiao, YL | 1 |
| Peng, S | 1 |
| Chen, J | 1 |
| Wen, WP | 1 |
| Chen, MH | 1 |
| Shimatani, T | 2 |
| Ishihara, S | 1 |
| Fujiwara, Y | 2 |
| Kusano, M | 2 |
| Chiba, T | 3 |
| Adachi, K | 2 |
| Furuta, K | 1 |
| Ito, M | 2 |
| Kurosawa, S | 1 |
| Manabe, N | 1 |
| Mannen, K | 1 |
| Miwa, H | 2 |
| Kobeissy, AA | 1 |
| Hashash, JG | 1 |
| Jamali, FR | 1 |
| Skoury, AM | 1 |
| Haddad, R | 1 |
| El-Samad, S | 1 |
| Ladki, R | 1 |
| Aswad, R | 1 |
| Soweid, AM | 1 |
| Laheij, RJ | 1 |
| Van Rossum, LG | 1 |
| Jansen, JB | 1 |
| Verheugt, FW | 1 |
| Gardner, JD | 1 |
| Sloan, S | 1 |
| Miner, PB | 2 |
| Pehlivanov, ND | 1 |
| Olyaee, M | 1 |
| Sarosiek, I | 1 |
| McCallum, RW | 1 |
| Hashimoto, T | 1 |
| Hamamoto, N | 1 |
| Hirakawa, K | 1 |
| Niigaki, M | 1 |
| Miyake, T | 1 |
| Taniura, H | 1 |
| Ono, M | 1 |
| Kaji, T | 1 |
| Suetsugu, H | 1 |
| Yagi, J | 1 |
| Komazawa, Y | 1 |
| Mihara, T | 1 |
| Katsube, T | 1 |
| Fujishiro, H | 1 |
| Shizuku, T | 1 |
| Hattori, S | 1 |
| Yamamoto, S | 1 |
| Bytzer, P | 2 |
| Blum, A | 1 |
| De Herdt, D | 1 |
| Dubois, D | 1 |
| Zentilin, P | 1 |
| Accornero, L | 1 |
| Dulbecco, P | 1 |
| Savarino, V | 1 |
| Inamori, M | 1 |
| Togawa, J | 1 |
| Iwasaki, T | 1 |
| Ozawa, Y | 1 |
| Kikuchi, T | 1 |
| Muramatsu, K | 1 |
| Chiguchi, G | 1 |
| Matsumoto, S | 1 |
| Kawamura, H | 1 |
| Abe, Y | 1 |
| Kirikoshi, H | 1 |
| Kobayashi, N | 1 |
| Shimamura, T | 1 |
| Kubota, K | 1 |
| Sakaguchi, T | 1 |
| Saito, S | 1 |
| Ueno, N | 1 |
| Nakajima, A | 1 |
| Tsuji, S | 1 |
| Kawano, S | 1 |
| Pace, F | 1 |
| Annese, V | 1 |
| Prada, A | 1 |
| Zambelli, A | 1 |
| Casalini, S | 1 |
| Nardini, P | 1 |
| Bianchi Porro, G | 1 |
| DeVault, KR | 1 |
| Rodriguez-Stanley, S | 1 |
| Bemben, D | 1 |
| Zubaidi, S | 1 |
| Redinger, N | 1 |
| Warrington, S | 1 |
| Baisley, K | 1 |
| Lee, D | 1 |
| Lomax, K | 1 |
| Boyce, M | 1 |
| Morocutti, A | 1 |
| Sasaki, M | 1 |
| Habu, Y | 1 |
| Wada, T | 1 |
| Nagahara, A | 1 |
| Morgan, DG | 1 |
| O'Mahony, MF | 1 |
| O'Mahony, WF | 1 |
| Roy, J | 1 |
| Camacho, F | 1 |
| Dinniwell, J | 1 |
| Horbay, GL | 1 |
| Husein-Bhabha, FA | 1 |
| Nojkov, B | 1 |
| Rubenstein, JH | 1 |
| Adlis, SA | 1 |
| Shaw, MJ | 1 |
| Saad, R | 1 |
| Rai, J | 1 |
| Weinman, B | 1 |
| Chey, WD | 1 |
| Farley, A | 1 |
| Wruble, LD | 1 |
| Humphries, TJ | 1 |
| Fitzgerald, S | 1 |
| Hegedus, R | 1 |
| Jokubaitis, L | 1 |
| Metz, M | 1 |
| Loeffler, V | 1 |
| Blum, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment Response of High-dose and Standard-dose Rabeprazole for Gastroesophageal Reflux Disease With Extra-esophageal Manifestations: a Single-center, Randomized, Open-label Trial.[NCT04001400] | Phase 3 | 73 participants (Actual) | Interventional | 2012-10-10 | Completed | ||
| The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT)[NCT00464308] | Phase 4 | 1,392 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn[NCT00237367] | Phase 4 | 52 participants (Actual) | Interventional | Completed | |||
| A Double-Blind, Placebo-Controlled Study of Rabeprazole 20 mg Maintenance Intermittent Therapy Following Acute Treatment in Patients Wth Symptomatic Gastroesophageal Reflux Disease[NCT00165841] | Phase 2 | 200 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)[NCT00658528] | Phase 3 | 1,061 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)[NCT00658775] | Phase 3 | 1,069 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| "Double-Blind Placebo-Controlled Randomized Withdrawal Trial Assessing the Efficacy and Tolerability of On-Demand Maintenance Therapy With 10mg o.d. Rabeprazole for 6 Months in Non-Erosive Reflux Disease Patients With Complete Symptom Relief After 4 Week [NCT00236392] | Phase 3 | 422 participants (Actual) | Interventional | 2001-10-31 | Completed | ||
| Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial[NCT01269788] | Phase 2/Phase 3 | 144 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00464308)
Timeframe: 4 weeks
| Intervention | percent of participants (Mean) |
|---|---|
| Rabeprazole 20 mg/Day | 56.3 |
| Esomeprazole 40 mg/Day | 63.4 |
| Esomeprazole 20 mg/Day | 56.1 |
(NCT00464308)
Timeframe: 4 weeks
| Intervention | days (Median) |
|---|---|
| Rabeprazole 20 mg/Day | 9 |
| Esomeprazole 40 mg/Day | 11 |
| Esomeprazole 20 mg/Day | 13 |
(NCT00464308)
Timeframe: week 4 of treatment
| Intervention | days (Median) |
|---|---|
| Rabeprazole 20 mg/Day | 11 |
| Esomeprazole 40 mg/Day | 9 |
| Esomeprazole 20 mg/Day | 12 |
Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe. (NCT00464308)
Timeframe: 4 weeks
| Intervention | participants (Number) |
|---|---|
| Rabeprazole 20 mg/Day | 281 |
| Esomeprazole 40 mg/Day | 283 |
| Esomeprazole 20 mg/Day | 276 |
Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild) assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe. (NCT00464308)
Timeframe: 4 weeks
| Intervention | participants (Number) |
|---|---|
| Rabeprazole 20 mg/Day | 405 |
| Esomeprazole 40 mg/Day | 418 |
| Esomeprazole 20 mg/Day | 414 |
Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild)assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe. (NCT00464308)
Timeframe: 4 weeks
| Intervention | participants (Number) |
|---|---|
| Rabeprazole 20 mg/Day | 397 |
| Esomeprazole 40 mg/Day | 413 |
| Esomeprazole 20 mg/Day | 402 |
Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe. (NCT00464308)
Timeframe: week 4 of treatment
| Intervention | participants (Number) |
|---|---|
| Rabeprazole 20 mg/Day | 272 |
| Esomeprazole 40 mg/Day | 302 |
| Esomeprazole 20 mg/Day | 278 |
The percentage of heartburn-free days during the 6-month Maintenance Treatment Phase in patients treated with rabeprazole 20 mg compared to patients who received placebo in the ITT Population. Heartburn-free day was defined as no heartburn in both the daytime and nighttime period on a given day. Note a total 388 subjects were enrolled at the beginning of Acute Phase and 200 subjects were enrolled into the double-blind 6-month maintenance treatment phase. (NCT00165841)
Timeframe: 6 months double-blind maintenance phase
| Intervention | Percentage of Days (Mean) |
|---|---|
| Rabeprazole 20 mg | 82.58 |
| Placebo | 62.17 |
During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of hearburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at least 7 consecutive heartburn-free days. (NCT00658528)
Timeframe: Week 4
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Yes | No | Missing | |
| ESO 40 mg | 48.2 | 46.3 | 5.5 |
| RAB ER 50 mg | 48.3 | 44.3 | 7.4 |
"Healing at week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade C or D from Baseline. Classifications include:~Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present).~Grade A: One or more mucosal breaks not more than 5 mm in maximum length. Grade B: One or more mucosal breaks more than 5 mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Grade D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00658528)
Timeframe: Baseline and Week 4
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Yes | No | Missing | |
| ESO 40 mg | 50.3 | 47.8 | 1.9 |
| RAB ER 50 mg | 54.8 | 42.6 | 2.7 |
"Healing at week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade C or D from Baseline. Classifications include:~Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present).~Grade A: One or more mucosal breaks not more than 5 mm in maximum length. Grade B: One or more mucosal breaks more than 5 mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Gread D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00658528)
Timeframe: Baseline and Week 8
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Yes | No | Missing | |
| ESO 40 mg | 75 | 20.3 | 4.7 |
| RAB ER 50 mg | 80 | 14.9 | 5.2 |
During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of heartburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at least 7 consecutive heartburn-free days. (NCT00658775)
Timeframe: Week 4
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Yes | No | Missing | |
| ESO 40mg | 52.5 | 40 | 7.4 |
| RAB ER 50mg | 53.2 | 39.6 | 7.2 |
"Healing at week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade C or D from Baseline. Classifications include:~Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Grade D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00658775)
Timeframe: Baseline and Week 4
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Yes | No | Missing | |
| ESO 40mg | 50.7 | 46.4 | 3 |
| RAB ER 50mg | 50.9 | 47 | 2.1 |
"Healing at week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade C or D from Baseline. Classifications include:~Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Grade D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00658775)
Timeframe: Baseline and Week 8
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Yes | No | Missing | |
| ESO 40mg | 78.4 | 16.6 | 5 |
| RAB ER 50mg | 77.5 | 18.4 | 4.2 |
5 reviews available for rabeprazole and Pyrosis
| Article | Year |
|---|---|
Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis.
Topics: Adult; Bayes Theorem; Esophagitis; Gastroesophageal Reflux; Heartburn; Humans; Network Meta-Analysis | 2022 |
Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.
Topics: Adult; Alginates; Dexlansoprazole; Endoscopy, Gastrointestinal; Gastroesophageal Reflux; Gastrointes | 2023 |
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; | 2017 |
Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Esophagus; Gastroesophageal Reflux; Heartburn; | 2011 |
Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Endoscopy, Digestive Sys | 2006 |
25 trials available for rabeprazole and Pyrosis
| Article | Year |
|---|---|
Efficacy of a high-dose proton pump inhibitor in patients with gastroesophageal reflux disease: a single center, randomized, open-label trial.
Topics: Gastroesophageal Reflux; Heartburn; Humans; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2020 |
Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2009 |
Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dose-Response Relationship, Drug; Endoscopy, Gastroin | 2010 |
Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Inflammatory Agents, Non-Steroid | 2010 |
Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Stud | 2010 |
Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response R | 2010 |
Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, | 2011 |
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Double-Blind Method; Esomeprazole; | 2011 |
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Double-Blind Method; Esomeprazole; | 2011 |
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Double-Blind Method; Esomeprazole; | 2011 |
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Double-Blind Method; Esomeprazole; | 2011 |
Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophageal pH Monitoring; Female; | 2011 |
Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research G
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; | 2011 |
Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Chi-Square Distribution; Esophageal pH M | 2012 |
A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Female; Gastroesophageal Reflux; Heartburn; Histamin | 2012 |
Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2003 |
Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Cross- | 2003 |
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2003 |
Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blin | 2004 |
Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Administration, Oral; Adult; Benzimidazoles; Cr | 2005 |
Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance o
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Benzimidazoles; Dose-Re | 2005 |
Effect of esophageal acid and prophylactic rabeprazole on performance in runners.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophagus; Exercise Test; Female; | 2006 |
Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Stud | 2007 |
Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Dose-Response Relationsh | 2007 |
Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Benzimidazoles; D | 2000 |
Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Esophagitis | 2002 |
A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2002 |
9 other studies available for rabeprazole and Pyrosis
| Article | Year |
|---|---|
Control of acid and duodenogastroesophageal reflux (DGER) in patients with Barrett's esophagus.
Topics: Aged; Barrett Esophagus; Bilirubin; Deglutition Disorders; Esophageal pH Monitoring; Female; Gastroe | 2015 |
Characteristics of symptomatic reflux episodes in Japanese proton pump inhibitor-refractory non-erosive reflux disease patients.
Topics: Adult; Aged; Asian People; Drug Administration Schedule; Drug Resistance; Electric Impedance; Esopha | 2015 |
Characteristics of symptomatic reflux episodes in patients with non-erosive reflux disease who have a positive symptom index on proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Esophageal pH Monitoring; Female; Gastroesopha | 2010 |
Comparison of patients of chronic laryngitis with and without troublesome reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Anti-Ulcer Agents; Chronic Disease; End | 2012 |
Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Body Mass Index; Esophagitis, Pept | 2012 |
Air swallowing can be responsible for non-response of heartburn to high-dose proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aerophagy; Anti-Ulcer Agents; Benzimidazoles; Dose-R | 2005 |
A new-generation H2 receptor antagonist: quicker and stronger acid inhibition than proton pump inhibitors in the clinical setting?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Benzimidazoles; Gastric Acid; Gastric Acidity D | 2005 |
Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Enzyme Inhibitors; Female; | 2007 |
The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Female; Gastroesophageal Reflux; H | 2008 |